Autopsy report · NCT03901573

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

“Strategic decision by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 3 years 8 months before it stopped.
• 31 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

NeoImmuneTech

Sponsor type

Industry

Conditions

Melanoma; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma

Interventions

NT-I7; atezolizumab

Participants

31

Sites

8

Countries

United States

Trials that died the same way

• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (98% match in meaning)
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
  “Sponsor's strategic decision” (98% match in meaning)
• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
  “Strategic sponsor decision” (98% match in meaning)
• Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
  “Sponsor decision due to strategic considerations” (95% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.